China (Mainland)
Bevacizumab
- Min.Order: 0 Metric Ton
- Payment Terms: T/T
- Product Details
Keywords
- Bevacizumab
- Anti-Human VEGF
- Humanized Antibody
Quick Details
- ProName: Bevacizumab
- Appearance: Colorless to light yellow (Liquid)
- Application: Bevacizumab, a humanized monoclonal an...
- DeliveryTime: In stock
- PackAge: 1mg, 5mg
- Port: Shanghai, China
- ProductionCapacity: Metric Ton/Day
- Purity: >99.0%
- Storage: Store at 4°C,Do not freeze
- Transportation: By Air
- LimitNum: 0 Metric Ton
Superiority
Product Name: Bevacizumab
Appearance: Colorless to light yellow (Liquid)
Purity (CE-SDS): >99.0%
Concentration: 25 mg/ml
pH Value: 6.1
Endotoxin Level: <2 EU/ml
Sterility Test: PASS
Activity: 1E4 U/mg
Details
Biological Activity:
In Vitro: Bevacizumab, a humanized monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity, and inhibits its interaction with VEGFR-1 and VEGFR-2. Experimental analysis shows that the EC50 of Bevacizumab to bind VEGF analyzed by ELISA is 0.18 μg/mL. Binding kinetics assays show similar results that Bevacizumab inhibits the VEGF-induced proliferation of HUVEC with an IC50 value of 0.047±0.0081 μg/mL.
In Vivo: It is demonstrated that the subconjunctival administration of FD006, Bevacizumab and Dexamethasone can all significantly inhibit CoNV in NaOH cauterized rats compared with the control group (p < 0.01). The combination of NVP-LDE225 and Paclitaxel causes a long-lasting antitumor activity, with a tumor size of 1.64 cm3 at the end of the experiment, whereas Bevacizumab plus Paclitaxel-treated mice reaches the maximum allowed tumor size on day 84.